Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tecan Group AGLTS:0QLN +0.54%77 Debt-to-Equity is 0.19 as of Dec. 2025, which is 46% above its 10-year median of 0.13. GuruFocus rates LTS:0QLN with a GF Score™ of 77/100 and a GF Value™ of CHF243.78 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Tecan Group AG ranks better than 54.18% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Tecan Group AG's Debt-to-Equity or its related term are showing as below:
LTS:0QLN'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.13 Max: 0.26
Current: 0.19
During the past 13 years, the highest Debt-to-Equity Ratio of Tecan Group AG was 0.26. The lowest was 0.00. And the median was 0.13.
LTS:0QLN's Debt-to-Equity is ranked better than 54.18% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs LTS:0QLN: 0.19
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Tecan Group AG Debt-to-Equity Related Terms
Tecan Group AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Tecan Group AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0QLN vs ISRG, BDX, MDLN: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Tecan Group AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tecan Group AG Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tecan Group AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Tecan Group AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tecan Group AG (LTS:0QLN) has a Debt-to-Equity of 0.19 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Tecan Group AG and its competitors. This is 46% above median its historical median of 0.13. According to the industry distribution chart, Tecan Group AG ranks #323 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 45.8%.
Is Tecan Group AG's Debt-to-Equity too high?
Tecan Group AG's current Debt-to-Equity of 0.19 is 46% above median its 10-year median of 0.13. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Tecan Group AG's value of 0.19 is 17.4% below this industry median. Based on the distribution chart, Tecan Group AG ranks #323 out of 705 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Tecan Group AG has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tecan Group AG's Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tecan Group AG ranks #323 out of 705 companies for Debt-to-Equity. This puts Tecan Group AG in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Tecan Group AG's value of 0.19 is 17.4% below this benchmark. While the company's 10-year median is 0.13 vs. the industry median of 0.23, Tecan Group AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tecan Group AG's current Debt-to-Equity of 0.19 is 17.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Tecan Group AG and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tecan Group AG's current Debt-to-Equity is 0.19, which is 46% above median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tecan Group AG stock overvalued right now?
Based on GuruFocus' analysis, Tecan Group AG (LTS:0QLN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF243.78, compared to a current price of CHF194.64 — trading 20.2% below its estimated fair value. The current Debt-to-Equity is 0.19, which is 46% above median its 10-year median of 0.13 and 17.4% below the Medical Devices & Instruments industry median of 0.23. Tecan Group AG's overall GF Score™ is 77/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Tecan Group AG (LTS:0QLN), the current Debt-to-Equity is 0.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tecan Group AG (LTS:0QLN) Overvalued in 2026?
Based on GuruFocus' analysis, Tecan Group AG stock appears to be undervalued.
The current stock price of CHF194.64 is trading 20.2% below its estimated GF Value™ of CHF243.78.
GuruFocus considers Tecan Group AG to be Modestly Undervalued.
Key valuation signals for LTS:0QLN:
Debt-to-Equity: 0.19 (46% above median its 10-year median of 0.13)
GF Value™: CHF243.78 vs. price of CHF194.64 (20.2% below fair value)
Industry Position: 17.4% below the Medical Devices & Instruments median (#323 of 705)
No single metric tells the full story. See the LTS:0QLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tecan Group AG sells automated laboratory instruments and solutions for the diagnostics and life sciences research markets. The firm operates in two segments; The Life Sciences Business (end-customer business) segment supplies end users with automated workflow solutions directly. These solutions include laboratory instruments, software packages, application know-how, services, consumables, and spare parts, The partnering Business (OEM business) segment develops and manufactures OEM instruments and components that are distributed by partner companies under their names. A majority proportion of Tecan's revenue is generated in the Americas and Europe followed by Asia Specific.
77GF Score
Get the complete analysis for LTS:0QLN
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QLN has been successfully added to your 
